Dynamic Impacts of the Inhibition of the Molecular Chaperone Hsp90 on the T-Cell Proteome Have Implications for Anti-Cancer Therapy

Abstract

The molecular chaperone Hsp90-dependent proteome represents a complex protein network of critical biological and medical relevance. Known to associate with proteins with a broad variety of functions termed clients, Hsp90 maintains key essential and oncogenic signalling pathways. Consequently, Hsp90 inhibitors are being tested as anti-cancer drugs. Using an integrated systematic approach to analyse the effects of Hsp90 inhibition in T-cells, we quantified differential changes in the Hsp90-dependent proteome, Hsp90 interactome, and a selection of the transcriptome. Kinetic behaviours in the Hsp90-dependent proteome were assessed using a novel pulse-chase strategy (Fierro-Monti et al., accompanying article), detecting effects on both protein stability and synthesis. Global and specific dynamic impacts, including proteostatic responses, are due to direct inhibition of Hsp90 as well as indirect effects. As a result, a decrease was detected in most proteins that changed their levels, including known Hsp90 clients. Most likely, consequences of the role of Hsp90 in gene expression determined a global reduction in net de novo protein synthesis. This decrease appeared to be greater in magnitude than a concomitantly observed global increase in protein decay rates. Several novel putative Hsp90 clients were validated, and interestingly, protein families with critical functions, particularly the Hsp90 family and cofactors themselves as well as protein kinases, displayed strongly increased decay rates due to Hsp90 inhibitor treatment. Remarkably, an upsurge in survival pathways, involving molecular chaperones and several oncoproteins, and decreased levels of some tumour suppressors, have implications for anti-cancer therapy with Hsp90 inhibitors. The diversity of global effects may represent a paradigm of mechanisms that are operating to shield cells from proteotoxic stress, by promoting pro-survival and anti-proliferative functions. Data are available via ProteomeXchange with identifier PXD000537.

Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling

“…This approach, which was originally developed to provide accurate and data-driven normalization factors to quantitative real-time PCR data, 42 was then applied to RNA sequencing count data to identify the most variable genomic features 43 and successfully usedto normalize the nCounter miRNA assay count data as well. 44,45 Differences in exosome concentration between healthy donors and CLL patients, as well as IGHV-mutated and -unmutated CLL patients, were examined using 2-sample t tests with unequal variances. Paired t tests or mixed effects models were used to assess differences in exosome concentration/production between conditions within patient samples (eg,, ibrutinib in the presence of a-IgM stimulation vs stimulation alone).…”

Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas

“…There is also the concern that H90Ins could impact the effectiveness of tumor suppressor pathways (Fierro-Monti et al 2013); (Manjarrez et al 2014). HSP90 interacts with a large portion of the proteome and is involved in maintaining tumor promoting as well as tumor suppressing cellular components (Taipale et al 2014); (Nony et al 2003).…”

Recent Advances in Macrocyclic Hsp90 Inhibitors

“…34,35 The majority of Hsp90's activity occurs in the cytosol, where it forms protein-protein interactions with approximately 60% of all cellular kinases and 30% of all ubiquitin ligases. 34,36 In addition, Hsp90 contributes to the maturation of hormone receptors and kinases that are essential for oncogenesis in hormone-dependent cancers.…”

“…Recent proteomic studies have shown that geldanamycin alters cellular protein levels through a decrease in de novo protein synthesis and a reduction in protein stability. 35,64 The complex and interlinking protein networks that are affected by geldanamycin form one arm of the apoptotic process, but the induction of metabolic stress through the reduction of the compound also contributes to cell death. Two enzymes metabolise the benzoquinone moiety of geldanamycin and enhance the macrocycle's potency or contribute to its toxicity.…”